$PALI
PALISADE BIO, INC.

2017 Q1 Form 10-Q Financial Statement

#000117184317002892 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $2.500K $2.500K
YoY Change 0.0% -14.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.330M $3.170M
YoY Change -58.04% 121.68%
% of Gross Profit
Research & Development $2.902M $3.066M
YoY Change -5.33% -3.68%
% of Gross Profit
Depreciation & Amortization $110.0K $90.00K
YoY Change 22.22% 12.5%
% of Gross Profit
Operating Expenses $4.235M $6.236M
YoY Change -32.1% 35.1%
Operating Profit -$4.232M -$6.234M
YoY Change -32.11% 35.13%
Interest Expense $138.7K $386.5K
YoY Change -64.11% -14.82%
% of Operating Profit
Other Income/Expense, Net -$3.335M -$372.2K
YoY Change 796.16% -15.45%
Pretax Income -$7.570M -$6.610M
YoY Change 14.52% 30.89%
Income Tax
% Of Pretax Income
Net Earnings -$7.567M -$6.606M
YoY Change 14.55% 30.73%
Net Earnings / Revenue -302690.16% -264231.32%
Basic Earnings Per Share
Diluted Earnings Per Share -$84.11M -$110.2M
COMMON SHARES
Basic Shares Outstanding 92.04M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.68M $7.620M
YoY Change 118.9% -73.38%
Cash & Equivalents $11.68M $7.621M
Short-Term Investments $5.000M $0.00
Other Short-Term Assets $480.0K $1.080M
YoY Change -55.56% 107.69%
Inventory
Prepaid Expenses $477.1K $1.078M
Receivables $14.72K $39.17K
Other Receivables $0.00 $0.00
Total Short-Term Assets $17.17M $8.738M
YoY Change 96.53% -70.03%
LONG-TERM ASSETS
Property, Plant & Equipment $242.8K $337.0K
YoY Change -27.94% 19.47%
Goodwill
YoY Change
Intangibles $904.7K $1.067M
YoY Change -15.17% -14.13%
Long-Term Investments
YoY Change
Other Assets $15.82K $57.69K
YoY Change -72.57% -2.38%
Total Long-Term Assets $1.556M $1.461M
YoY Change 6.5% -11.23%
TOTAL ASSETS
Total Short-Term Assets $17.17M $8.738M
Total Long-Term Assets $1.556M $1.461M
Total Assets $18.73M $10.20M
YoY Change 83.63% -66.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.170M $2.630M
YoY Change -17.49% 23.47%
Accrued Expenses $0.00 $290.0K
YoY Change -100.0% 26.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.531M $4.466M
YoY Change -43.33% 131.52%
Total Short-Term Liabilities $5.048M $7.621M
YoY Change -33.77% 75.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.546M
YoY Change -100.0% -63.39%
Other Long-Term Liabilities $3.900M $200.0K
YoY Change 1850.0% 33.33%
Total Long-Term Liabilities $3.900M $2.546M
YoY Change 53.16% -63.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.048M $7.621M
Total Long-Term Liabilities $3.900M $2.546M
Total Liabilities $8.949M $10.37M
YoY Change -13.69% -9.35%
SHAREHOLDERS EQUITY
Retained Earnings -$200.6M -$178.6M
YoY Change 12.34% 14.39%
Common Stock $117.4K $920.4K
YoY Change -87.24% 1.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.780M -$169.4K
YoY Change
Total Liabilities & Shareholders Equity $18.73M $10.20M
YoY Change 83.63% -66.89%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$7.567M -$6.606M
YoY Change 14.55% 30.73%
Depreciation, Depletion And Amortization $110.0K $90.00K
YoY Change 22.22% 12.5%
Cash From Operating Activities -$4.436M -$3.490M
YoY Change 27.1% -26.06%
INVESTING ACTIVITIES
Capital Expenditures $14.60K
YoY Change -9.06%
Acquisitions
YoY Change
Other Investing Activities $0.00 $7.520M
YoY Change -100.0% -37700.0%
Cash From Investing Activities $7.490M
YoY Change -7590.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00K $0.00
YoY Change
Debt Paid & Issued, Net $1.223M $1.097M
YoY Change 11.45%
Cash From Financing Activities 921.7K -1.100M
YoY Change -183.79% -118.68%
NET CHANGE
Cash From Operating Activities -4.436M -3.490M
Cash From Investing Activities 7.490M
Cash From Financing Activities 921.7K -1.100M
Net Change In Cash -3.514M 2.900M
YoY Change -221.18% 171.03%
FREE CASH FLOW
Cash From Operating Activities -$4.436M -$3.490M
Capital Expenditures $14.60K
Free Cash Flow -$4.436M -$3.505M
YoY Change 26.58% -26.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 cur Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
2167615
CY2016Q4 cur Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
2343936
CY2017Q1 cur Expenses Related To Issuance Of Derivative Instrument
ExpensesRelatedToIssuanceOfDerivativeInstrument
476084
CY2016Q1 cur Expenses Related To Issuance Of Derivative Instrument
ExpensesRelatedToIssuanceOfDerivativeInstrument
CY2017Q1 cur Fees Related To Issuance Of Derivative Instrument And Other Expenses
FeesRelatedToIssuanceOfDerivativeInstrumentAndOtherExpenses
476084
CY2016Q1 cur Fees Related To Issuance Of Derivative Instrument And Other Expenses
FeesRelatedToIssuanceOfDerivativeInstrumentAndOtherExpenses
-3199
CY2017Q1 cur Payments Of Fees Related To Prior Financing
PaymentsOfFeesRelatedToPriorFinancing
11596
CY2016Q1 cur Payments Of Fees Related To Prior Financing
PaymentsOfFeesRelatedToPriorFinancing
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
189462
CY2017Q1 cur Proceeds From Exercise Of Stock Purchase Warrants Net Of Issuance Costs
ProceedsFromExerciseOfStockPurchaseWarrantsNetOfIssuanceCosts
2200004
CY2016Q1 cur Proceeds From Exercise Of Stock Purchase Warrants Net Of Issuance Costs
ProceedsFromExerciseOfStockPurchaseWarrantsNetOfIssuanceCosts
CY2017Q1 cur Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue
15.46
CY2016Q4 cur Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedNumber
6863
CY2017Q1 cur Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedNumber
6210
CY2017Q1 cur Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber
6210
CY2017Q1 cur Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue
32.29
CY2016Q4 cur Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested And Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue
30.70
CY2017Q1 cur Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested And Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValue
32.29
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14715
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10491
CY2017Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
852963
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3734
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3905
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210249148
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
204239837
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
522439
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1470886
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
47654
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8300000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3100000
CY2016Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017Q1 us-gaap Assets
Assets
18728492
CY2016Q4 us-gaap Assets
Assets
22604328
CY2017Q1 us-gaap Assets Current
AssetsCurrent
17172286
CY2016Q4 us-gaap Assets Current
AssetsCurrent
20904716
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11680499
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15194949
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4716533
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7620746
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3514450
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2904213
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
16700000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11032858
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
117432
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
110329
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7567425
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6607556
CY2017Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.01
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.01
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11743244
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
112205
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
85467
CY2017Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2741314
CY2016Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2017Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3884972
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3921917
CY2017Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
CY2016Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
53081
CY2017Q1 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
392840
CY2016Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
424240
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-184
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-723
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y255D
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1732000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1332421
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3170522
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-227650
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1170334
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4224
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1851
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-852963
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
125684
CY2017Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-84481
CY2016Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
CY2017Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12542
CY2016Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
49177
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
159
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-14029
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2080
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-67646
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-221649
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-82020
CY2017Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
904732
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
990153
CY2017Q1 us-gaap Interest Expense
InterestExpense
138732
CY2016Q1 us-gaap Interest Expense
InterestExpense
386506
CY2017Q1 us-gaap Interest Paid
InterestPaid
136718
CY2016Q1 us-gaap Interest Paid
InterestPaid
205827
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
20883
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
11136
CY2017Q1 us-gaap Liabilities
Liabilities
8948725
CY2016Q4 us-gaap Liabilities
Liabilities
11273550
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18728492
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22604328
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5047624
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7333424
CY2017Q1 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
16129
CY2016Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
18209
CY2017Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
2530922
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3705787
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
921696
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1096951
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
7490108
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4435962
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3488221
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-7567254
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6605783
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3335247
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-372171
CY2017Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
4234507
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
6236112
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4232007
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6233612
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15824
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15662
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-171
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1773
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
349087
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
430738
CY2017Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
CY2016Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12747
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14598
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
10000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
10000
CY2017Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
477072
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
646195
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
7517453
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242810
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
269557
CY2017Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1222519
CY2016Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1096951
CY2017Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
94193
CY2016Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2902086
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3065590
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200600547
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193033293
CY2017Q1 us-gaap Revenues
Revenues
2500
CY2016Q1 us-gaap Revenues
Revenues
2500
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
522439
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1470886
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
653
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4700000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1394323
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
25.36
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7693
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
200928
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1691987
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1684294
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.60
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.57
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.20
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2017Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1684294
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1604
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y36D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y328D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y36D
CY2017Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
22.57
CY2017Q1 us-gaap Short Term Investments
ShortTermInvestments
5000000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
5000000
CY2017Q1 us-gaap Stock Issued1
StockIssued1
CY2016Q1 us-gaap Stock Issued1
StockIssued1
38337
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
9779767
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
11330778
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white">The preparation of financial statements in accordance with United States of America generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our derivative instruments and our stock-based compensation related to employees and directors, consultants and investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</div></div></div></div>
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11140898
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7077676

Files In Submission

Name View Source Status
0001171843-17-002892-index-headers.html Edgar Link pending
0001171843-17-002892-index.html Edgar Link pending
0001171843-17-002892.txt Edgar Link pending
0001171843-17-002892-xbrl.zip Edgar Link pending
cur-20170331.xml Edgar Link completed
cur-20170331.xsd Edgar Link pending
cur-20170331_cal.xml Edgar Link unprocessable
cur-20170331_def.xml Edgar Link unprocessable
cur-20170331_lab.xml Edgar Link unprocessable
cur-20170331_pre.xml Edgar Link unprocessable
exh_311.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_051017p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pipeline.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending